Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Corporate Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases June 13, 2022 FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata June 13, 2022 Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 May 26, 2022 Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting All press releases Latest Events Jun 14 2022 Jun 14 2022 Goldman Sachs Global Healthcare Conference Webcast May 17 2022 May 17 2022 RBC Capital Markets Healthcare Conference Webcast All events
